Avlon Pharma partners for drug licensing in Kingdom

Alcal announced that Middle East Pharmaceuticals "Avalon Pharma" has signed an exclusive licensing agreement with "One Source for Specialized Pharmaceuticals Limited" to register and market the drug Terzipatide in Saudi Arabia and the Middle East and North Africa markets for up to 10 years from the launch. It is expected that the drug will achieve cumulative revenues of at least 800 million riyals within the first five years of its release. The drug focuses on the treatment of metabolic and diabetic diseases, and the agreement aims to expand the company's portfolio and strengthen its regional presence.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل